0000950170-22-023843.txt : 20221109 0000950170-22-023843.hdr.sgml : 20221109 20221109160909 ACCESSION NUMBER: 0000950170-22-023843 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221109 DATE AS OF CHANGE: 20221109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alpha Teknova, Inc. CENTRAL INDEX KEY: 0001850902 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 943368109 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40538 FILM NUMBER: 221372637 BUSINESS ADDRESS: STREET 1: 2451 BERT DRIVE CITY: HOLLISTER STATE: CA ZIP: 95023 BUSINESS PHONE: 8316371100 MAIL ADDRESS: STREET 1: 2451 BERT DRIVE CITY: HOLLISTER STATE: CA ZIP: 95023 8-K 1 tkno-20221109.htm 8-K 8-K
false000185090200018509022022-11-092022-11-09

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 2054

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 9, 2022

 

ALPHA TEKNOVA, INC.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

 

Delaware

 

001-40538

 

94-3368109

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

2451 Bert Drive

Hollister, CA 95023

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (831) 637-1100

N/A

(Former name, or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.00001 per share

 

TKNO

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

On November 9, 2022, Alpha Teknova, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2022 (the “Press Release”). A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including the Press Release, is intended to be furnished under Item 2.02 and Item 9.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

 

Description

99.1

 

Press Release issued by Alpha Teknova, Inc., dated November 9, 2022

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

ALPHA TEKNOVA, INC.

Date: November 9, 2022

By:

/s/ Stephen Gunstream

 

 

Stephen Gunstream

 

 

President and Chief Executive Officer

 

 

 EX-99.1 2 tkno-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

img201297901_0.jpg 

 

Teknova Reports Third Quarter 2022 Financial Results

 

Third quarter 2022 total revenue was $10.7 million, up 14% year-over-year

Company updates 2022 revenue outlook to $40-42 million

Cash position of $50 million supports path to profitability

 

 

HOLLISTER, Calif., November 9, 2022 – Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, research, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2022.

 

“Teknova delivered a solid third quarter revenue performance, driven by robust Lab Essentials growth and healthy demand across our broad customer base,” said Stephen Gunstream, President and CEO of Teknova. “Most recently, we entered the qualification phase of our new state-of-the-art production facility and announced an Early Access Program for the first novel products to emerge from our R&D pipeline. We are balancing selective strategic investments with prudent management of our capital to position Teknova for accelerated growth and remain on our path to profitability.”

 

Corporate and Financial Updates

 

•
Achieved quarterly total revenue of $10.7 million, up 14% compared to $9.4 million in the third quarter 2021
•
Remained on track with capacity expansion of existing facilities and are nearing completion of the Company’s new, state-of-the-art manufacturing facility. Qualification activities are underway, and facility expected to be operational for production of research grade products by the end of 2022
•
Reported cash position of $49.9 million, supporting ongoing investment in future growth
•
Introduced an Early Access Program for two novel products in development and added WFI Quality Water to the Company’s product portfolio
•
Goodwill was fully impaired, resulting in a one-time, non-cash impairment charge of $16.6 million in the third quarter 2022

 

1

 

Revenue for the Third Quarter and Year-to-Date 2022

 

 

 

For the Three Months Ended September 30,

 

 

For the Nine Months Ended September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Lab Essentials

 

$

9,470

 

 

$

7,195

 

 

$

24,838

 

 

$

20,440

 

Clinical Solutions

 

 

919

 

 

 

1,690

 

 

 

7,673

 

 

 

4,354

 

Sample Transport

 

 

—

 

 

 

73

 

 

 

6

 

 

 

1,035

 

Other

 

 

303

 

 

 

434

 

 

 

1,012

 

 

 

954

 

Total revenue

 

$

10,692

 

 

$

9,392

 

 

$

33,529

 

 

$

26,783

 

 

Third Quarter 2022 Financial Results

 

Total revenue for the third quarter 2022 was $10.7 million, up 14% compared to $9.4 million in the third quarter 2021.

 

Gross profit for the third quarter 2022 was $4.8 million, compared to $4.3 million in the third quarter 2021. Gross margin for the third quarter 2022 was 44.6% of revenue. This compares to gross margin of 45.4% in the third quarter 2021. The lower gross margin for the third quarter 2022 compared to the gross margin in the prior year primarily reflects additional headcount resulting in higher labor costs.

 

Operating expenses for the third quarter 2022 were $27.7 million compared to $8.2 million in the third quarter 2021. The increase was primarily related to a one-time, $16.6 million non-cash goodwill impairment charge in the quarter, coupled with additional headcount, stock-based compensation expense, and marketing costs.

 

Net loss for the third quarter 2022 was $22.5 million, or negative $0.80 per diluted share, compared to net loss of $3.3 million, or negative $0.12 per diluted share, for the third quarter 2021.

 

Cash used in operating activities for the third quarter 2022 was $8.3 million, compared to cash used in operating activities of $4.8 million for the third quarter 2021.

 

Adjusted EBITDA for the third quarter 2022 was negative $4.6 million, compared to negative $2.7 million for the third quarter 2021. Free Cash Flow was negative $14.9 million for the third quarter 2022, compared to negative $8.7 million for the third quarter 2021.

 

2022 Revenue Outlook

 

Teknova is updating its outlook for the fiscal year ending December 31, 2022, to total revenue of $40 million to $42 million, which assumes approximately 16% growth at the mid-point of guidance, excluding Sample Transport revenue earned in 2021. The Company expects an approximately 15% increase in Lab Essentials and at least a 25% increase in Clinical Solutions revenue to drive total revenue growth for the year. The Company does not anticipate any material revenue from Sample Transport in 2022.

2

 

 

Conference Call and Webcast

 

Teknova will host a webcast and conference call on Wednesday, November 9, 2022, beginning at 4:30 p.m. ET. Participants can access the live webcast on the Investor Relations section of the Teknova website and at this link: https://edge.media-server.com/mmc/p/rjjxxr67. To receive a PIN number for dial in, participants can register for the webcast via this link: https://register.vevent.com/register/BIc8c72fb8e9214c49b689933915e724ad. The webcast will be available for replay on the Company’s website approximately two hours after the event.

 

About Teknova

 

Teknova is expediting clinical breakthroughs in life sciences by providing custom products and reagents for drug therapies, novel vaccines, and molecular diagnostics. With a focus on agility and customization, Teknova delivers research-grade and GMP products, including cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a multitude of established and emerging applications, including cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Teknova's proprietary processes enable the manufacture and delivery of high-quality, custom, made-to-order products with short turnaround times and at scale across all stages of development, including commercialization.

 

Non-GAAP Financial Measures

 

This press release contains financial measures that have not been calculated in accordance with U.S. generally accepted accounting principles (GAAP). Teknova uses the following non-GAAP financial measures in assessing the performance of its business and the effectiveness of its business strategies: (a) Adjusted EBITDA and (b) Free Cash Flow.

 

Teknova defines Adjusted EBITDA as net loss adjusted for interest income (expense), net, benefit from income taxes, depreciation expense, amortization of intangible assets, and stock-based compensation expense. Adjusted EBITDA reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other items that Teknova does not consider representative of its ongoing operating performance.

 

Teknova defines Free Cash Flow as cash used in operating activities less purchases of property, plant, and equipment.

 

Teknova presents Adjusted EBITDA and Free Cash Flow in this press release because Teknova believes that analysts, investors, and other interested parties frequently use these measures to evaluate companies in Teknova's industry and that such measures facilitate comparisons on a consistent basis across reporting periods. Teknova also believes such measures are helpful in highlighting trends in Teknova's operating results because they exclude items that are not indicative of Teknova's core operating performance. Investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial

3

 

performance prepared in accordance with GAAP. The non-GAAP financial measures presented by Teknova may be different from the non-GAAP financial measures used by other companies.

 

A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.

 

Forward-Looking Statements

 

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to Teknova’s anticipated total revenue, expected growth in Lab Essentials and Clinical Solutions, ongoing capacity expansion, new research and development products, prospects, including to achieve profitability, and long-term growth strategy. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management’s current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond Teknova’s control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, demand for Teknova’s products (including the delay or pausing of customer orders); Teknova’s assessment of fundamental indicators of future demand across its target customer base; Teknova’s ability to expand its production capacity and commercial and R&D capabilities; Teknova’s cash flows and revenue growth rate; Teknova’s supply chain, sourcing, manufacturing and warehousing; inventory management; risks related to global economic and marketplace uncertainties related to the impact of the COVID-19 pandemic, including the impact of the pandemic on Teknova’s supply chain; reliance on a limited number of customers for a high percentage of Teknova’s revenue; potential acquisitions and integration of other companies and other factors discussed in the “Risk Factors” section of Teknova’s most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including in Teknova’s Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q filed with the SEC, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although Teknova believes that the expectations reflected in its forward-looking statements are reasonable, Teknova does not know whether its expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by Teknova on its website or otherwise. Teknova does not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

 

4

 

Investor Contacts Media Contact

Matt Lowell Jenn Henry

Chief Financial Officer Senior Vice President, Marketing

matt.lowell@teknova.com jenn.henry@teknova.com

+1 831-637-1100 +1 831-313-1259

 

Sara Michelmore

MacDougall Advisors

smichelmore@macdougall.bio

+1 781-235-3060

 

 

5

 

ALPHA TEKNOVA, INC.

Condensed Statements of Operations

(Unaudited)

(In thousands, except share and per share data)

 

 

 

For the Three Months Ended September 30,

 

 

For the Nine Months Ended September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Revenue

 

$

10,692

 

 

$

9,392

 

 

$

33,529

 

 

$

26,783

 

Cost of sales

 

 

5,922

 

 

 

5,129

 

 

 

18,163

 

 

 

14,141

 

Gross profit

 

 

4,770

 

 

 

4,263

 

 

 

15,366

 

 

 

12,642

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

1,925

 

 

 

1,372

 

 

 

5,867

 

 

 

2,922

 

Sales and marketing

 

 

2,397

 

 

 

885

 

 

 

6,592

 

 

 

2,494

 

General and administrative

 

 

6,502

 

 

 

5,607

 

 

 

20,856

 

 

 

13,606

 

Amortization of intangible assets

 

 

287

 

 

 

287

 

 

 

861

 

 

 

861

 

Goodwill impairment

 

 

16,613

 

 

 

—

 

 

 

16,613

 

 

 

—

 

Total operating expenses

 

 

27,724

 

 

 

8,151

 

 

 

50,789

 

 

 

19,883

 

Loss from operations

 

 

(22,954

)

 

 

(3,888

)

 

 

(35,423

)

 

 

(7,241

)

Other income (expenses), net

 

 

 

 

 

 

 

 

 

 

 

 

Interest income (expense), net

 

 

70

 

 

 

(255

)

 

 

85

 

 

 

(553

)

Other income (expense), net

 

 

36

 

 

 

—

 

 

 

36

 

 

 

(2

)

Total other income (expenses), net

 

 

106

 

 

 

(255

)

 

 

121

 

 

 

(555

)

Loss before income taxes

 

 

(22,848

)

 

 

(4,143

)

 

 

(35,302

)

 

 

(7,796

)

Benefit from income taxes

 

 

(374

)

 

 

(892

)

 

 

(1,128

)

 

 

(1,640

)

Net loss

 

$

(22,474

)

 

$

(3,251

)

 

$

(34,174

)

 

$

(6,156

)

Net loss per share—basic and diluted

 

$

(0.80

)

 

$

(0.12

)

 

$

(1.22

)

 

$

(0.51

)

Weighted average shares used in computing net loss per share—basic and diluted

 

 

28,090,267

 

 

 

28,011,917

 

 

 

28,059,897

 

 

 

12,069,214

 

 

 

6

 

ALPHA TEKNOVA, INC.

Condensed Balance Sheets

(Unaudited)

(In thousands)

 

 

 

As of September 30,

 

 

As of December 31,

 

 

 

2022

 

 

2021

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

49,855

 

 

$

87,518

 

Accounts receivable, net

 

 

5,581

 

 

 

4,666

 

Contract assets

 

 

667

 

 

 

—

 

Inventories, net

 

 

10,323

 

 

 

5,394

 

Income taxes receivable

 

 

120

 

 

 

1,188

 

Prepaid expenses and other current assets

 

 

3,521

 

 

 

2,438

 

Total current assets

 

 

70,067

 

 

 

101,204

 

Property, plant and equipment, net

 

 

52,628

 

 

 

29,810

 

Operating right-of-use lease assets

 

 

18,558

 

 

 

—

 

Goodwill

 

 

—

 

 

 

16,613

 

Intangible assets, net

 

 

17,843

 

 

 

18,704

 

Other non-current assets

 

 

1,176

 

 

 

180

 

Total assets

 

$

160,272

 

 

$

166,511

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

3,485

 

 

$

2,248

 

Accrued liabilities

 

 

6,590

 

 

 

5,495

 

Current portion of operating lease liabilities

 

 

2,253

 

 

 

—

 

Total current liabilities

 

 

12,328

 

 

 

7,743

 

Deferred tax liabilities

 

 

2,028

 

 

 

3,153

 

Other accrued liabilities

 

 

212

 

 

 

273

 

Long-term debt, net

 

 

16,878

 

 

 

11,870

 

Deferred rent

 

 

—

 

 

 

269

 

Long-term operating lease liabilities

 

 

16,830

 

 

 

—

 

Total liabilities

 

 

48,276

 

 

 

23,308

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock

 

 

—

 

 

 

—

 

Common stock

 

 

—

 

 

 

—

 

Additional paid-in capital

 

 

153,708

 

 

 

150,741

 

Accumulated deficit

 

 

(41,712

)

 

 

(7,538

)

Total stockholders’ equity

 

 

111,996

 

 

 

143,203

 

Total liabilities and stockholders’ equity

 

$

160,272

 

 

$

166,511

 

 

 

7

 

ALPHA TEKNOVA, INC.

Condensed Statements of Cash Flows

(Unaudited)

(In thousands)

 

 

 

For the Three Months Ended September 30,

 

 

For the Nine Months Ended September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(22,474

)

 

$

(3,251

)

 

$

(34,174

)

 

$

(6,156

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Bad debt expense

 

 

2

 

 

 

4

 

 

 

34

 

 

 

235

 

Inventory reserve

 

 

186

 

 

 

(23

)

 

 

178

 

 

 

676

 

Depreciation and amortization

 

 

729

 

 

 

748

 

 

 

2,272

 

 

 

2,100

 

Stock-based compensation

 

 

968

 

 

 

442

 

 

 

2,689

 

 

 

927

 

Deferred taxes

 

 

(374

)

 

 

(893

)

 

 

(1,125

)

 

 

(1,640

)

Amortization of debt financing costs

 

 

60

 

 

 

43

 

 

 

159

 

 

 

89

 

Non-cash lease expense

 

 

75

 

 

 

11

 

 

 

256

 

 

 

60

 

Loss on disposal of property, plant and equipment

 

 

210

 

 

 

—

 

 

 

210

 

 

 

4

 

Goodwill impairment

 

 

16,613

 

 

 

 

 

 

16,613

 

 

 

—

 

Other

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(10

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

  Accounts receivable

 

 

227

 

 

 

(504

)

 

 

(949

)

 

 

(170

)

  Contract assets

 

 

(667

)

 

 

—

 

 

 

(667

)

 

 

—

 

  Inventories

 

 

(2,600

)

 

 

(500

)

 

 

(5,107

)

 

 

(1,497

)

  Income taxes receivable

 

 

(3

)

 

 

447

 

 

 

1,068

 

 

 

226

 

  Prepaid expenses and other current assets

 

 

(1,820

)

 

 

(2,195

)

 

 

(1,083

)

 

 

(1,777

)

  Other non-current assets

 

 

(407

)

 

 

2

 

 

 

(996

)

 

 

(5

)

  Accounts payable

 

 

1,247

 

 

 

501

 

 

 

969

 

 

 

468

 

  Accrued liabilities

 

 

(283

)

 

 

348

 

 

 

343

 

 

 

553

 

  Other

 

 

(21

)

 

 

(17

)

 

 

(61

)

 

 

(70

)

    Cash used in operating activities

 

 

(8,332

)

 

 

(4,837

)

 

 

(19,371

)

 

 

(5,987

)

Investing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Purchase of property, plant and equipment

 

 

(6,582

)

 

 

(3,907

)

 

 

(23,419

)

 

 

(12,465

)

Proceeds from loan to related party

 

 

—

 

 

 

—

 

 

 

—

 

 

 

529

 

Proceeds on sales of short-term marketable securities

 

 

—

 

 

 

—

 

 

 

—

 

 

 

1,132

 

Proceeds from maturities of short-term marketable securities

 

 

—

 

 

 

—

 

 

 

—

 

 

 

695

 

    Cash used in investing activities

 

 

(6,582

)

 

 

(3,907

)

 

 

(23,419

)

 

 

(10,109

)

Financing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Proceeds from long-term debt

 

 

—

 

 

 

1

 

 

 

5,135

 

 

 

11,890

 

Payment of debt issuance costs

 

 

—

 

 

 

—

 

 

 

(151

)

 

 

(153

)

Payment of exit fee costs

 

 

—

 

 

 

—

 

 

 

(135

)

 

 

—

 

Payment of costs related to initial public offering

 

 

—

 

 

 

(1,266

)

 

 

—

 

 

 

(3,615

)

Proceeds from initial public offering, net of underwriters’ commissions and discounts

 

 

—

 

 

 

—

 

 

 

—

 

 

 

102,672

 

Proceeds from exercise of stock options

 

 

35

 

 

 

—

 

 

 

134

 

 

 

—

 

Proceeds from issuance of common stock under employee stock purchase plan

 

 

—

 

 

 

—

 

 

 

144

 

 

 

—

 

    Cash provided by financing activities

 

 

35

 

 

 

(1,265

)

 

 

5,127

 

 

 

110,794

 

Change in cash and cash equivalents

 

 

(14,879

)

 

 

(10,009

)

 

 

(37,663

)

 

 

94,698

 

Cash and cash equivalents at beginning of period

 

 

64,734

 

 

 

108,022

 

 

 

87,518

 

 

 

3,315

 

Cash and cash equivalents at end of period

 

$

49,855

 

 

$

98,013

 

 

$

49,855

 

 

$

98,013

 

 

 

8

 

ALPHA TEKNOVA, INC.

Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures

(Unaudited)

(In thousands)

 

 

 

For the Three Months Ended September 30,

 

 

For the Nine Months Ended September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Net loss – as reported

 

$

(22,474

)

 

$

(3,251

)

 

$

(34,174

)

 

$

(6,156

)

Add back:

 

 

 

 

 

 

 

 

 

 

 

 

Interest income (expense), net

 

 

70

 

 

 

(255

)

 

 

85

 

 

 

(553

)

Benefit from income taxes

 

 

(374

)

 

 

(892

)

 

 

(1,128

)

 

 

(1,640

)

Depreciation expense

 

 

442

 

 

 

461

 

 

 

1,411

 

 

 

1,239

 

Amortization of intangible assets

 

 

287

 

 

 

287

 

 

 

861

 

 

 

861

 

EBITDA

 

$

(22,189

)

 

$

(3,140

)

 

$

(33,115

)

 

$

(5,143

)

Other and one-time expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

968

 

 

 

442

 

 

 

2,689

 

 

 

927

 

Goodwill impairment charge

 

 

16,613

 

 

 

—

 

 

 

16,613

 

 

 

—

 

Adjusted EBITDA

 

$

(4,608

)

 

$

(2,698

)

 

$

(13,813

)

 

$

(4,216

)

 

 

 

For the Three Months Ended September 30,

 

 

For the Nine Months Ended September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Cash used in operating activities

 

$

(8,332

)

 

$

(4,837

)

 

$

(19,371

)

 

$

(5,987

)

Purchase of property, plant and equipment

 

 

(6,582

)

 

 

(3,907

)

 

 

(23,419

)

 

 

(12,465

)

Free Cash Flow

 

$

(14,914

)

 

$

(8,744

)

 

$

(42,790

)

 

$

(18,452

)

 

9

 

 GRAPHIC 3 img201297901_0.jpg GRAPHIC begin 644 img201297901_0.jpg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end EX-101.SCH 4 tkno-20221109.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 5 tkno-20221109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 6 tkno-20221109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Ex Transition Period Entity Ex Transition Period Amendment Flag Amendment Flag Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code City Area Code City Area Code Document Period End Date Document Period End Date Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity File Number Entity File Number Entity Address, Address Line One Entity Address, Address Line One Entity Tax Identification Number Entity Tax Identification Number Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Pre-commencement Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Title of 12(b) Security Entity Address, State or Province Entity Address, State or Province Document Type Document Type Written Communications Written Communications Security Exchange Name Security Exchange Name Entity Address, Address Line Two Entity Address, Address Line Two Entity Central Index Key Entity Central Index Key Local Phone Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover [Abstract] Trading Symbol Trading Symbol XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document And Entity Information
Nov. 09, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 09, 2022
Entity Registrant Name ALPHA TEKNOVA, INC.
Entity Central Index Key 0001850902
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity File Number 001-40538
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 94-3368109
Entity Address, Address Line One 2451 Bert Drive
Entity Address, City or Town Hollister
Entity Address, State or Province CA
Entity Address, Postal Zip Code 95023
City Area Code 831
Local Phone Number 637-1100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.00001 per share
Trading Symbol TKNO
Security Exchange Name NASDAQ
XML 8 tkno-20221109_htm.xml IDEA: XBRL DOCUMENT 0001850902 2022-11-09 2022-11-09 false 0001850902 8-K 2022-11-09 ALPHA TEKNOVA, INC. DE 001-40538 94-3368109 2451 Bert Drive Hollister CA 95023 831 637-1100 false false false false Common Stock, par value $0.00001 per share TKNO NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ".!:54'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " C@6E55U6F-NX K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2@,Q$(9?17+?G60K0L,VEXHG!<&"XBTDTS:XV81D9+=O[VYLMX@^@,?,_/GF M&YC61&E"PN<4(B9RF&]&W_59FKAA1Z(H ;(YHM>YGA+]U-R'Y#5-SW2 J,V' M/B TG-^!1])6DX896,6%R%1KC30)-85TQENSX.-GZ@K,&L ./?:40=0"F)HG MQM/8M7 %S##"Y/-W >U"+-4_L:4#[)P621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M ".!:54[8B+&<@0 "P1 8 >&PO=V]R:W-H965T&UL MI9AK;^I&$(;_RLJMJE8*\85+( 4DAR0-2@ZA@9XCM>J'Q5Y@%=OK[JXA_/O. M&K YJ1DC]0O8QO/Z\>SXG3']K9#O:LV8)A]QE*B!M=8ZO;5M%:Q93-6U2%D" MORR%C*F&7;FR52H9#?.@.+(]Q^G8,>6)->SGQZ9RV!>9CGC"II*H+(ZIW-VQ M2&P'EFL=#[SQU5J; _:PG](5FS']1SJ5L&<7*B&/6:*X2(ADRX'EN[=W7ML$ MY&=\Y6RK3K:)N96%$.]F9QP.+,<0L8@%VDA0^-JP$8LBHP0<_QQ$K>*:)O!T M^ZC^F-\\W,R"*C82T3<>ZO7 ZEHD9$N:1?I-;)_8X89RP$!$*O\DV_VYK99% M@DQI$1^"@2#FR?Z;?AP2<1K0/!/@'0*\G'M_H9SRGFHZ[$NQ)=*<#6IF([_5 M/!K@>&)69:8E_,HA3@_O19!!DC7QDY \))KK'1DG^]6&K/5M#1E?$W*J4!&UA0N(K)#;.&/_W@=IQ?$;YFP=?$U,L$SG5U M5%=(G8*M@RH>BON-K;@I)8"O_I79#P972-T-P7= MS25T(TB>I!$\@B'[(,]L5\6'*SF.XW;;3L_!DM8ML+J78#W$3*YXLB*_0;Q> MDY&(4YI4PN%Z6F98G?4*K-Y%6!]D#BNI>&[P^YJK8L+%ZHK?=4HO=2[!>N01 M(Y,L7C!9Z9^X""Q?H^6TFUT,Z<3>W4N0QDD@9"ID;NI79*;AH21"PD)F4'!0 M=R*L?!1JU.\?,,C2XEW4H8^0<_I!QB$\ 7S)@YP4RR(NV6LUFLU.UW5Z&&%I M\BYNTP="/PRA@ZBKXP9Y@?/(:U*=.US2:[5=D)O<2!A,,LVP#+N[CGS%' M9@^6>2ZVU:TX.+6_IGN*((IU)L>!)4)Q'7'/D86MD: MW(MZ0X$V%4J#"__)T_-/!J[8:SM>$V,K&X.+^WF^ACY,W.=1<(%NT\5 RE;@ MXM[](@+(R70M$M3=<)%.\Z;ANHZ#$95=P,6=^YOD6K/$M*,X2PZ>H2JI_E\+ M\,H6X.'N/1,1#Z ?0:_\ N4M.8TJ)U96QEO%D MN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY# M;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? M KP(&K XU7=>&18/QA<0 M&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH M!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)? MA+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+ M"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TU MMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PEY7>>9 ]IV03NA1.XJRY/K% M.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?#$T%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$# M#RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q M_G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@" MIQ%', ; 4/2='@//GL?)=-[*CG_5U/\!%!+ P04 " C@6E5EXJ[', M 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D! M5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]I MSI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\= MQ_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( ".! M:54ZJJ+G0 $ #P" / >&PO=V]R:V)O;VLN>&ULC5%=:\,P#/PKQC]@ M20SH\0RVT+E6J:'3"T4\ M4V#C-E4DYPH]&09;B(S5'WC3B?PT9>H1-N6'$2&%GN5"6&-,W&_T_$8T'D&6 MA^[ ](2.(2X-PW.D0XMAU]&(B^S"1I_#6(<0Y_$_,5)=8P5+J@X> @\Y1G"= MP) :;)-6P7@H]+BB[H-5CX$E)+4* Y7L=D[E],H.KEGD7F08YRB#N+*#\%&M MA1H#V#:;7-Y-;2>C@W(-@[^&5C!W-CQ]W]P-02P,$% M @ (X%I520>FZ*M ^ $ !H !X;"]? M+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2 M*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+B MRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L# M!!0 ( ".!:55ED'F2&0$ ,\# 3 6T-O;G1E;G1?5'EP97-=+GAM M;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL M>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE M@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J M1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/; M&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G= M560C2&2FKW@ALO7L^T%.6X.^D&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( ".!:54[8B+&<@0 M "P1 8 " @0T( !X;"]W;W)K&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " C@6E599!Y MDAD! #/ P $P @ ',$@ 6T-O;G1E;G1?5'EP97-=+GAM 7;%!+!08 "0 ) #X" 6% ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports tkno-20221109.htm tkno-20221109.xsd tkno-20221109_lab.xml tkno-20221109_pre.xml tkno-ex99_1.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tkno-20221109.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tkno-20221109.htm" ] }, "labelLink": { "local": [ "tkno-20221109_lab.xml" ] }, "presentationLink": { "local": [ "tkno-20221109_pre.xml" ] }, "schema": { "local": [ "tkno-20221109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "tkno", "nsuri": "http://www.teknova.com/20221109", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tkno-20221109.htm", "contextRef": "C_232f0fb9-6636-45e0-93ef-614e0338831d", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tkno-20221109.htm", "contextRef": "C_232f0fb9-6636-45e0-93ef-614e0338831d", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.teknova.com/20221109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0000950170-22-023843-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-023843-xbrl.zip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end